Grown Rogue International (GRUSF) Cash from Financing Activities (2013 - 2026)

Grown Rogue International's (GRUSF) quarterly Cash from Financing Activities came in at $2.7 million in Q1 2026, down 41.3% year-on-year from $4.5 million in Q1 2025, and up 100.0% quarter-over-quarter from -$10136.9 billion in Q4 2025.

Grown Rogue International (GRUSF) Cash from Financing Activities (2013 - 2026) Analysis & Trends

Grown Rogue International's Cash from Financing Activities history runs 14 years deep, the most recent figure standing at $2.7 million for Q1 2026.

  • On a quarterly basis, Cash from Financing Activities fell 41.3% year-over-year to $2.7 million in Q1 2026; TTM through Mar 2026 was -$10136.9 billion, a 299677216.8% decrease from a year earlier, with the FY2025 full-year figure at $9.8 million, up 117.4% from the prior year.
  • Cash from Financing Activities climbed to $2.7 million in Q1 2026 per GRUSF's latest filing, from -$10136.9 billion in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $4.5 million in Q1 2025 and bottomed at -$10136.9 billion in Q4 2025.
  • The 5-year median for Cash from Financing Activities is $871165.0 (2022), against an average of -$844.7 billion.
  • Biggest YoY gain for Cash from Financing Activities was 34.62% in 2025; the steepest drop was 3604482049.28% in 2025.
  • Year by year, Cash from Financing Activities stood at $944368.0 in 2022, then jumped by 162.2% to $2.5 million in 2023, then sank by 111.36% to -$281230.6 in 2024, then sank by 3604482049.28% to -$10136.9 billion in 2025, then jumped by 100.0% to $2.7 million in 2026.
  • Per Business Quant, the three latest GRUSF Cash from Financing Activities figures stand at $2.7 million (Q1 2026), -$10136.9 billion (Q4 2025), and $4.5 million (Q1 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 13.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn -840.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -494.13 Mn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -1.48 Bn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn -203.80 Mn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn -86.10 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -65.00 Mn
10 Grown Rogue International 99.97 Mn 92.67 Mn 3.96 Mn 2.67 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 2.67 Mn
Mar 31, 2026 2.67 Mn
Dec 31, 2025 -10,136.91 Bn
Dec 31, 2025 -10,136.91 Bn
Mar 31, 2025 4.55 Mn
Mar 31, 2025 4.55 Mn
Dec 31, 2024 -281,230.64
Dec 31, 2024 -281,230.64
Sep 30, 2024 -200,531.89
Sep 30, 2024 -200,531.89
Jun 30, 2024 -683,206.97
Jun 30, 2024 -683,206.97
Mar 31, 2024 3.38 Mn
Mar 31, 2024 3.38 Mn
Oct 31, 2023 2.48 Mn
Oct 31, 2023 2.48 Mn
Jul 31, 2023 3.08 Mn
Jul 31, 2023 3.08 Mn
Apr 30, 2023 -731,322.00
Apr 30, 2023 -731,322.00